SYNDAX PHARMACEUTICALS INC's ticker is SNDX and the CUSIP is 87164F105. A total of 137 filers reported holding SYNDAX PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,160,660 | +220.0% | 699,770 | +361.3% | 0.01% | +150.0% |
| Q2 2023 | $3,175,081 | +360295.1% | 151,700 | +263.5% | 0.00% | +100.0% |
| Q1 2023 | $881 | -99.8% | 41,728 | +69.6% | 0.00% | – |
| Q2 2022 | $473,000 | -93.6% | 24,601 | -94.2% | 0.00% | -100.0% |
| Q1 2022 | $7,406,000 | +1701.9% | 426,113 | +2171.1% | 0.00% | – |
| Q4 2021 | $411,000 | -41.6% | 18,762 | -49.1% | 0.00% | – |
| Q3 2021 | $704,000 | -79.9% | 36,851 | -81.9% | 0.00% | -100.0% |
| Q2 2021 | $3,500,000 | -79.2% | 203,845 | -73.1% | 0.00% | -83.3% |
| Q4 2020 | $16,839,000 | +41.0% | 757,147 | -6.4% | 0.01% | -20.0% |
| Q3 2020 | $11,945,000 | -6.5% | 809,290 | -6.1% | 0.02% | -16.7% |
| Q2 2020 | $12,776,000 | +314.3% | 862,048 | +206.7% | 0.02% | +157.1% |
| Q1 2020 | $3,084,000 | +172.2% | 281,091 | +117.9% | 0.01% | +600.0% |
| Q4 2019 | $1,133,000 | -34.3% | 129,021 | -44.1% | 0.00% | -50.0% |
| Q3 2019 | $1,724,000 | +351.3% | 230,795 | +461.9% | 0.00% | +100.0% |
| Q2 2019 | $382,000 | +8.2% | 41,077 | -38.8% | 0.00% | 0.0% |
| Q1 2019 | $353,000 | -77.4% | 67,155 | -80.8% | 0.00% | -50.0% |
| Q4 2018 | $1,560,000 | -79.1% | 350,465 | -62.0% | 0.00% | -77.8% |
| Q3 2018 | $7,457,000 | +612.9% | 922,938 | +519.7% | 0.01% | +800.0% |
| Q2 2018 | $1,046,000 | -78.5% | 148,935 | -56.4% | 0.00% | -83.3% |
| Q1 2018 | $4,857,000 | +7.3% | 341,313 | -33.9% | 0.01% | 0.0% |
| Q4 2017 | $4,525,000 | -10.9% | 516,500 | +18.9% | 0.01% | -25.0% |
| Q3 2017 | $5,081,000 | -52.2% | 434,244 | -43.0% | 0.01% | -57.9% |
| Q2 2017 | $10,634,000 | +160.6% | 761,203 | +155.9% | 0.02% | +171.4% |
| Q1 2017 | $4,081,000 | +469.2% | 297,480 | +197.3% | 0.01% | +250.0% |
| Q4 2016 | $717,000 | +423.4% | 100,065 | +621.0% | 0.00% | – |
| Q2 2016 | $137,000 | -78.2% | 13,879 | -70.5% | 0.00% | -100.0% |
| Q1 2016 | $628,000 | – | 47,114 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,600,000 | $52,272,000 | 8.55% |
| Foresite Capital Management IV, LLC | 875,000 | $12,705,000 | 7.06% |
| Aisling Capital Management LP | 1,025,000 | $14,883,000 | 6.13% |
| Saturn V Capital Management LP | 807,969 | $11,731,710 | 4.91% |
| Eversept Partners, LP | 2,596,245 | $37,697,477 | 3.19% |
| ACUTA CAPITAL PARTNERS, LLC | 297,035 | $4,312,948 | 2.89% |
| Paradigm Biocapital Advisors LP | 2,390,077 | $34,703,918 | 2.36% |
| DAFNA Capital Management LLC | 458,373 | $6,655,576 | 2.07% |
| SPHERA FUNDS MANAGEMENT LTD. | 773,061 | $11,224,846 | 2.04% |
| PFM Health Sciences, LP | 2,715,235 | $39,425,212 | 1.86% |